Document Type
Article
Publication Date
2-7-2024
Original Citation
Tanner G,
Barrow R,
Ajaib S,
Al-Jabri M,
Ahmed N,
Pollock S,
Finetti M,
Rippaus N,
Bruns A,
Syed K,
Poulter J,
Matthews L,
Hughes T,
Wilson E,
Johnson C,
Varn F,
Brüning-Richardson A,
Hogg C,
Droop A,
Gusnanto A,
Care M,
Cutillo L,
Westhead D,
Short S,
Jenkinson M,
Brodbelt A,
Chakrabarty A,
Ismail A,
Verhaak R,
Stead L.
IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy. Genome Biol. 2024;25(1):45.
Keywords
JGM, Humans, Glioblastoma, Neoplasm Recurrence, Local, Brain Neoplasms, Brain, DNA Methylation, Gene Expression Regulation, Neoplastic, Tumor Microenvironment
JAX Source
Genome Biol. 2024;25(1):45.
ISSN
1474-760X
PMID
38326875
DOI
https://doi.org/10.1186/s13059-024-03172-3
Abstract
BACKGROUND: Glioblastoma (GBM) brain tumors lacking IDH1 mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur.
RESULTS: Using RNA sequencing data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumors, we identify two responder subtypes based on longitudinal changes in gene expression. In two thirds of patients, a specific subset of genes is upregulated from primary to recurrence (Up responders), and in one third, the same genes are downregulated (Down responders), specifically in neoplastic cells. Characterization of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms that are associated with distinct changes in the tumor microenvironment. In Up responders, recurrent tumors are enriched in quiescent proneural GBM stem cells and differentiated neoplastic cells, with increased interaction with the surrounding normal brain and neurotransmitter signaling, whereas Down responders commonly undergo mesenchymal transition. ChIP-sequencing data from longitudinal GBM tumors suggests that the observed transcriptional reprogramming could be driven by Polycomb-based chromatin remodeling rather than DNA methylation.
CONCLUSIONS: We show that the responder subtype is cancer-cell intrinsic, recapitulated in in vitro GBM cell models, and influenced by the presence of the tumor microenvironment. Stratifying GBM tumors by responder subtype may lead to more effective treatment.
Comments
Open Access © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the mate‑ rial. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publi cdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.